This presentation on the identification and management of tardive dyskinesia 2022 reviews the relative prevalence of TD in patients with schizophrenia, mood spectrum disorders, and anxiety disorders; and the effective use of VMAT2 inhibitors without discontinuing other essential psychiatric treatments such as antipsychotics and antidepressants.